Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AbbVie Rival Boehringer Persuades PTAB To Reexamine Humira Patent

Executive Summary

Like Coherus BioSciences Inc., Boehringer Ingelheim GMBH convinced the US Patent & Trademark Office's Patent Trial and Appeal Board to back the company's inter partes review petition and institute a trial to consider the validity of certain claims on a patent held by AbbVie Inc. on its top-selling drug Humira (adalimumab), which also is facing competition from Amgen Inc., whose biosimilar application is under FDA review and is going before an advisory committee July 12.

You may also be interested in...



AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims

'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.

AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims

'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.

Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar

Amgen Inc. appears to have a smooth path to FDA approval of its biosimilar of AbbVie Inc.'s tumor necrosis factor Humira (adalimumab) based on documents released ahead of a July 12 advisory committee meeting. But don't expect AbbVie to just sit back and take it.

Topics

Related Companies

UsernamePublicRestriction

Register

PS118730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel